Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders

BACKGROUND: Clinical trials of immunotherapy have excluded patients with pre-existing autoimmune disease. While the safety and efficacy of single agent ipilimumab and anti-PD1 antibodies in patients with autoimmune disease has been examined in retrospective studies, no data are available for combina...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Brown, Lauren J, Weppler, Alison, Bhave, Prachi, Allayous, Clara, Patrinely Jr, J. Randall, Ott, Patrick, Sandhu, Shahneen, Haydon, Andrew, Lebbe, Celeste, Johnson, Douglas B, Long, Georgina V, Menzies, Alexander A, Carlino, Matteo S
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2021
Assuntos:
Clinical/Translational Cancer Immunotherapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8108669/
https://ncbi.nlm.nih.gov/pubmed/33963010
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-002121
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados